Results 1 to 10 of about 53,113 (297)

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors [PDF]

Current Oncology, 2021
This Phase Ib study combined programmed death-ligand 1 inhibitor, atezolizumab, with other immunomodulatory agents in locally advanced and metastatic solid tumors.
Christian U. Blank, Deborah J. Wong, Thai H. Ho, Todd M. Bauer, Carrie B. Lee, Fabiola Bene-Tchaleu, Jing Zhu, Xiaosong Zhang, Edward Cha, Mario Sznol   +9 more
doaj   +2 more sources

Post marketing safety surveillance of atezolizumab based on a retrospective analysis of the FDA adverse events reporting system (FAERS) [PDF]

Scientific Reports
Atezolizumab has been widely used for the immunotherapy of various cancers. This study aims to analyze the adverse events (AEs) associated with Atezolizumab post-marketing using the FDA Adverse Event Reporting System (FAERS). We conducted a retrospective
Gan Zhang, Danfeng Yu, Huan Pan, Jiong Liu, Ruling Wang, Yunyan Wan, Wuhua Zhou, Huaxiang Wang   +7 more
doaj   +2 more sources

Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study. [PDF]

ESMO Open
Kuemmel S, Jung KH, Andrade L, Assad-Suzuki D, de la Cruz Merino L, Freitas-Junior R, Hegg R, Huang CS, Martin H, Schneeweiss A, Dieterich M, Nguyen Duc A, Feng Y, Meng R, Swat A, Seiller A, Bermejo B, Hamilton EP.   +17 more
europepmc   +2 more sources

Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis

Frontiers in Immunology, 2021
BackgroundAtezolizumab plus chemotherapy has been recommended as a first-line treatment option for patients with advanced non-small cell lung carcinoma (NSCLC) irrespective of programmed cell death-ligand 1 (PD-L1) expression.
Dan-Ni Li, Dan-Ni Li, Dan-Ni Li, Wen-Qing Lu, Wen-Qing Lu, Wen-Qing Lu, Bo-Wen Yang, Bo-Wen Yang, Bo-Wen Yang, Ling-Yun Zhang, Ling-Yun Zhang, Ling-Yun Zhang, Bo Jin, Bo Jin, Bo Jin, Shuo Wang, Shuo Wang, Shuo Wang, Xiao-Fang Che, Xiao-Fang Che, Xiao-Fang Che, Ce Li, Ce Li, Ce Li, Yun-Peng Liu, Yun-Peng Liu, Yun-Peng Liu, Xiu-Juan Qu, Xiu-Juan Qu, Xiu-Juan Qu   +29 more
doaj   +1 more source

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

JTO Clinical and Research Reports, 2021
Introduction: The programmed death-ligand 1 inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated advanced NSCLC.
Rathi N. Pillai, MD, Suresh S. Ramalingam, MD, Meena Thayu, MD, Patricia Lorenzini, RN, Diana A. Alvarez Arias, PhD, Christopher Moy, MS, Natalie Hutnick, PhD, Roland Knoblauch, MD, Huaibao Feng, PhD, Colleen Kane, PhD, Leora Horn, MD, Martin Reck, MD, Santiago Ponce, MD   +12 more
doaj   +1 more source

Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series

SAGE Open Medical Case Reports, 2023
Atezolizumab plus bevacizumab is the recommended first-line treatment for unresectable hepatocellular carcinoma, based on guidelines from the Barcelona Clinic Liver Cancer prognosis and treatment strategy.
Takenori Ichimura, Daisuke Ichikura, Miwa Hinata, Noriko Hida, Toshiyuki Baba   +4 more
doaj   +1 more source

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab

Liver Cancer, 2022
Introduction: In the Phase 3 IMbrave150 trial (NCT03434379), atezolizumab + bevacizumab demonstrated a clinically meaningful survival benefit over sorafenib in patients with unresectable hepatocellular carcinoma (HCC), including those with hepatitis B ...
Chiun Hsu, Michel Ducreux, Andrew X. Zhu, Shukui Qin, Masafumi Ikeda, Tae-You Kim, Peter R. Galle, Richard S. Finn, Ethan Chen, Ning Ma, Youyou Hu, Lindong Li, Ann-Lii Cheng   +12 more
doaj   +1 more source

Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer

EJNMMI Research, 2022
Background Programmed cell death 1 ligand 1(PD-L1) is overexpressed in many tumors. The radionuclide-labeled anti-PD-L1 monoclonal antibody can be used for imaging and therapy of PD-L1 overexpressing cancer.
Linhan Zhang, Sheng Zhao, Huijie Jiang, Rongjun Zhang, Mingyu Zhang, Wenbin Pan, Zhongqi Sun, Dandan Wang, Jinping Li   +8 more
doaj   +1 more source

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab

Frontiers in Immunology, 2021
BackgroundAt present, there is a lack of studies focusing on the survival prediction of patients with non-small cell lung cancer (NSCLC) receiving atezolizumab in light of gene mutation characteristic.MethodsPatients with NSCLC receiving atezolizumab ...
Jiamao Lin, Xiaohui Wang, Chenyue Zhang, Shuai Bu, Chenglong Zhao, Haiyong Wang   +5 more
doaj   +1 more source

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada

JTO Clinical and Research Reports, 2021
Introduction: The real-world data evaluating treatment outcomes of atezolizumab plus carboplatin-etoposide chemotherapy (atezolizumab) for extensive-stage SCLC (ESCLC) are lacking.
Anifat A. Elegbede, MSc, MbChB, Amanda J. Gibson, BSc, Andrea S. Fung, PhD, MD, Winson Y. Cheung, MD, MPH, Michelle L. Dean, BSc, D. Gwyn Bebb, BMBCh, PhD, Aliyah Pabani, MD   +6 more
doaj   +1 more source